AMENDMENTS TO THE CLAIMS

1. - 11. (Canceled)

12. (Currently amended) A method of treating neuralgia pain or neuropathic pain[[,]] in a mammal[[,]] comprising administering to <u>said mammal a patient in need thereof</u> a therapeutically effective amount of a combination of retigabine or a therapeutically utilizable salt thereof with a voltage-gated sodium channel inhibitor or a therapeutically utilizable salt thereof selected from the group consisting of tolperisone, eperisone, and silperisone.

13.-15. (Canceled)

- 16. (Withdrawn) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said sodium channel-inhibiting or -influencing are administered separately or consecutively.
- 17. (Withdrawn) The method of claim 12, where said pains are associated with neuralgias.
- 18. (Withdrawn) The method of claim 12, where said pains are associated with arthritis and arthrosis.
- 19. (Withdrawn) The method of claim 12, where said pains are associated with chronic or episodic tension headache.
- 20. (Withdrawn) The method of claim 12, where said pains originate from a cause selected from lower spastic paraparesis syndrome, disturbances of the spinal blood circulation, and cerebral paralysis involving lower spastic paresis).
- 21. (Withdrawn) The method of claim 12, where said pains originate from a cause selected from lower paraspasm, transverse myelitis, multiple sclerosis, heritable inferior spastic paraplegia ("Stuempel paraplegia").
- 22. (Withdrawn) The method of claim 12, where said pains are associated with tetraparesis in connection with cervical myelopathy, cervical brachialgia or vertebral dysplasia.

Application No.: 10/727,655

23. (Canceled)

24. (Previously presented) The method of claim 12, wherein said voltage-gated sodium channel inhibitor or therapeutically utilizable salt thereof is administered simultaneously with retigabine.

25. (Previously presented) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said voltage-gated sodium channel inhibitor are administered separately or consecutively.

26. (Previously presented) The method of claim 12, wherein said neuralgia pain or neuropathic pain is accompanied by an increase in muscle tone.

27. (Canceled).

28. (Currently amended) The method of any one of claim[[s]] 12 or 15, wherein said mammal is a human.